Truist Financial analyst Nicole Germino maintained a Buy rating on POINT Biopharma Global (PNT – Research Report) today and set a price target of $14.00. The company’s shares opened today at $5.96.
Germino covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Assembly Biosciences, and Fusion Pharmaceuticals. According to TipRanks, Germino has an average return of -25.3% and a 20.00% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for POINT Biopharma Global with a $18.43 average price target, implying a 209.23% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $10.98 and a one-year low of $4.25. Currently, POINT Biopharma Global has an average volume of 848K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Therapeutics Acquisition Corp is a blank check company.
Read More on PNT:
- Point Biopharma, Lantheus announce strategic collaboration for PNT2002, PNT2003
- Point Biopharma reports Q3 EPS (26c), consensus (28c)
- POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
- Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
